Pharmacological safety during pregnancy: the principles of teratogenesis and teratogenicity of drugs

Reshetko, О.V.; Луцевич, К. А.; Клименченко, Н И

doi:10.15690/pf.v13i2.1551

Cited by 3 publications

(1 citation statement)

References 94 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Важливо підкреслити, що найнебезпечнішим періодом для застосування переважної більшості лікарських засобів, причому і хімічного, і натурального походження, вважається І триместр вагітності (перші 12 гестаційних тижнів), коли у плода закладаються всі органи і системи. Саме на цьому терміні плід вважається найбільш уразливим для будь-яких хімічних і лікарських речовин [72].…”

Section: г і н е к о л о г і яunclassified

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today

Мамчур

Дронов

2021

RHW

View full text Add to dashboard Cite

One of the key and strategically important problems of modern gynecology both around the world and in Ukraine is infectious and inflammatory diseases (IVD) of the lower genital tract: according to various estimates, back in the 90s of the last century, this diagnosis was made in about 40 % of patients in gynecological hospitals. Over the first decade of the 21st century, the incidence rate of genital IVI increased 1.4 times in 18–24-year-old patients, and 1.8 times in 25–29-year-old patients. At the same time, the costs of diagnostics and treatment have increased, which reach 50-60% of all costs for the provision of gynecological care to the population.In the structure of gynecological morbidity, the indicator of the number of patients with infectious and inflammatory diseases of the genital area continues to occupy a leading position in terms of frequency in the population, amounting to 60.4-65.0%, however, information from different authors regarding their true prevalence is very contradictory. So, according to the materials of the 33rd European Congress of the International Union against for Sexually Transmitted Infections (IUSTI-Europe), bacterial vaginosis (BV) occurs in 12-80% of women, vulvovaginal candidiasis – VVC (at least one episode in life) - in 75%, aerobic vaginitis (AV) – in 15-25% [8]. According to other authors, the prevalence of BV is 24-30%, VVC – 9.7-11.7%, nonspecific (aerobic) vaginitis – 5.0-23.7%.Combined drugs Neo-Penotran® Forte and Gainomax have a high safety profile, which is due to the unique features of the pharmacokinetics and pharmacodynamics of their components. This determines the advantages in the speed of bactericidal action over other antibacterial and antimycotic agents. These drugs are highly effective in the local treatment of BV and vulvovaginal infections, reaching 98.5% in some nosologies.The effectiveness and safety of the use of Neo-Penotran® Forte and Gainomax in the treatment of infections of the female genital area served as the basis for their inclusion in standard treatment regimens according to indications, and their use is regulated by the normative documents of the Ministry of Health of Ukraine.

show abstract

Section: г і н е к о л о г і яunclassified

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today

Мамчур

Дронов

2021

RHW

View full text Add to dashboard Cite

show abstract

Ankylosing spondylitis and pregnancy: a current view on the problem

Кричевская¹,

Гандалоева²,

Дубинина³

2018

RJTAO

View full text Add to dashboard Cite

Ankylosing spondylitis (AS) more often develops in the 3rd and 4th decade of life when many women think about motherhood. Today, the view which has prevailed since the middle of the 20th century on AS as a male disease has been revised; the male to female ratio for this disease is approaching 1:1, which makes it urgent to study the problem of pregnancy in AS. The review gives the data available in the literature on fertility in AS, the interaction of the latter and pregnancy, and drug therapy during gestation. There is evidence for further investigations to clarify the course of AS, to optimize the assessment of its activity and patients' functional status, to identify markers for an exacerbation of the disease during pregnancy and after childbirth, and to standardize drug therapy when preparing for pregnancy and during the latter.

show abstract

Federation Pharmacological Safety in Pregnancy: Modern Knowledge, Practice and Pharmacoepidemiological Approaches to the Studying and Recognizing of Drugs with Teratogenic Risk

Луцевич

Reshetko

2019

Pediatr. farmakol.

View full text Add to dashboard Cite

One of the key issues in obstetric practice remains the lack or incompleteness of information on the teratogenicity of most drugs used by pregnant women. Uncertainty regarding teratogenic risks significantly affect the quality of information on drugs; nevertheless, counseling patients allows arriving at a more balanced solution regarding their risk in pregnancy. Determination of the most commonly taken drugs (prescription or OTC) in the first trimester of gestation and increase of knowledge on their embryofetal risks optimizes pharmacotherapy during pregnancy. Characteristics and epidemiological analysis of possible factors, including drugs, associated with the occurrence of congenital anomalies, are crucial for the development of prevention activities that have an impact on the incidence of defects.

show abstract

Pharmacological safety during pregnancy: the principles of teratogenesis and teratogenicity of drugs

Cited by 3 publications

References 94 publications

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today

Ankylosing spondylitis and pregnancy: a current view on the problem

Federation Pharmacological Safety in Pregnancy: Modern Knowledge, Practice and Pharmacoepidemiological Approaches to the Studying and Recognizing of Drugs with Teratogenic Risk

Contact Info

Product

Resources

About

Pharmacological safety during pregnancy: the principles of teratogenesis and teratogenicity of drugs

Cited by 3 publications

References 94 publications

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of ​​today

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of ​​today

Ankylosing spondylitis and pregnancy: a current view on the problem

Federation Pharmacological Safety in Pregnancy: Modern Knowledge, Practice and Pharmacoepidemiological Approaches to the Studying and Recognizing of Drugs with Teratogenic Risk

Contact Info

Product

Resources

About

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today